As you can tell from the name, the target therapy, by definition, as everybody understands it, should be targeting the right tumor with the right target with the right patients, and it is very sarcastic that in our field, although the anti-angiogenic therapy as a target therapy has been given to our patients for more than one decade, there are no single biomarkers identified...
As you can tell from the name, the target therapy, by definition, as everybody understands it, should be targeting the right tumor with the right target with the right patients, and it is very sarcastic that in our field, although the anti-angiogenic therapy as a target therapy has been given to our patients for more than one decade, there are no single biomarkers identified. And to date, most patients with sarcoma are given anti-angiogenic therapy in a trial-and-error approach, which means that a lot of these patients are given additional toxicities without giving them additional benefits of this drug. So we really want to improve this situation. So in this study, we really want to demonstrate the superiority of using a biomarker-driven approach rather than an all-comer approach in this study, and that’s the main advantage of our study.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
